50 related articles for article (PubMed ID: 26587319)
1. CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.
Huang RR; Chen Z; Kroeger N; Pantuck A; Said J; Kluger HM; Shuch B; Ye H
Clin Genitourin Cancer; 2024 Apr; 22(2):347-353. PubMed ID: 38195301
[TBL] [Abstract][Full Text] [Related]
2. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling.
Li S; Chen D; Guo H; Liu D; Yang C; Zhang R; Wang T; Zhang F; Bai X; Yang Y; Sun N; Zhang W; Zhang L; Zhao G; Peng L; Tu X; Tian W
Front Oncol; 2023; 13():1240061. PubMed ID: 37849799
[TBL] [Abstract][Full Text] [Related]
3. Re: CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma.
Jiang A; Liu Y; Lin A; Luo P; Wang L
Eur Urol; 2024 May; ():. PubMed ID: 38735819
[No Abstract] [Full Text] [Related]
4. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.
Ruf M; Moch H; Schraml P
Int J Cancer; 2016 Jul; 139(2):396-403. PubMed ID: 26945902
[TBL] [Abstract][Full Text] [Related]
5. Melanoma-expressed CD70 is involved in invasion and metastasis.
Pich C; Sarrabayrouse G; Teiti I; Mariamé B; Rochaix P; Lamant L; Favre G; Maisongrosse V; Tilkin-Mariamé AF
Br J Cancer; 2016 Jan; 114(1):63-70. PubMed ID: 26671750
[TBL] [Abstract][Full Text] [Related]
6. Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma.
Campbell L; Jasani B; Griffiths DF; Gumbleton M
Am J Cancer Res; 2015; 5(9):2838-48. PubMed ID: 26609489
[TBL] [Abstract][Full Text] [Related]
7. Infiltrating T cells promote renal cell carcinoma (RCC) progression via altering the estrogen receptor β-DAB2IP signals.
Yeh CR; Ou ZY; Xiao GQ; Guancial E; Yeh S
Oncotarget; 2015 Dec; 6(42):44346-59. PubMed ID: 26587829
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of CD70 and CD27.
Wajant H
Expert Opin Ther Targets; 2016 Aug; 20(8):959-73. PubMed ID: 26914723
[TBL] [Abstract][Full Text] [Related]
9. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
[TBL] [Abstract][Full Text] [Related]
10. GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment.
Tong Q; Li D; Yin Y; Cheng L; Ouyang S
J Inflamm Res; 2023; 16():4153-4164. PubMed ID: 37750170
[TBL] [Abstract][Full Text] [Related]
11. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
[TBL] [Abstract][Full Text] [Related]
12. A 44-gene set constructed for predicting the prognosis of clear cell renal cell carcinoma.
Wang Y; Wang Y; Liu F
Int J Mol Med; 2018 Dec; 42(6):3105-3114. PubMed ID: 30272265
[TBL] [Abstract][Full Text] [Related]
13. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.
Cabo M; Offringa R; Zitvogel L; Kroemer G; Muntasell A; Galluzzi L
Oncoimmunology; 2017; 6(12):e1371896. PubMed ID: 29209572
[TBL] [Abstract][Full Text] [Related]
14. Trial Watch: Immunotherapy plus radiation therapy for oncological indications.
Vacchelli E; Bloy N; Aranda F; Buqué A; Cremer I; Demaria S; Eggermont A; Formenti SC; Fridman WH; Fucikova J; Galon J; Spisek R; Tartour E; Zitvogel L; Kroemer G; Galluzzi L
Oncoimmunology; 2016; 5(9):e1214790. PubMed ID: 27757313
[TBL] [Abstract][Full Text] [Related]
15. Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma.
Ruf M; Moch H; Schraml P
Oncoimmunology; 2015 Dec; 4(12):e1049805. PubMed ID: 26587319
[TBL] [Abstract][Full Text] [Related]
16. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
[TBL] [Abstract][Full Text] [Related]
17. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma.
Benhamouda N; Sam I; Epaillard N; Gey A; Phan L; Pham HP; Gruel N; Saldmann A; Pineau J; Hasan M; Quiniou V; Nevoret C; Verkarre V; Libri V; Mella S; Granier C; Broudin C; Ravel P; De Guillebon E; Mauge L; Helley D; Jabla B; Chaput N; Albiges L; Katsahian S; Adam J; Mejean A; Adotevi O; Vano YA; Oudard S; Tartour E
Clin Cancer Res; 2022 Nov; 28(22):4983-4994. PubMed ID: 36067339
[TBL] [Abstract][Full Text] [Related]
18. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
19. Control of lymphocyte function through CD27-CD70 interactions.
Lens SM; Tesselaar K; van Oers MH; van Lier RA
Semin Immunol; 1998 Dec; 10(6):491-9. PubMed ID: 9826582
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
